Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.

Abstract:

BACKGROUND:The addition of a low dose of ritonavir to protease inhibitors (PIs) has become a widespread strategy to improve PI pharmacokinetics. As resistance is a major barrier to long-term suppression, in salvage therapy genotype and/or phenotype scoring is currently used to predict the response. We evaluated the relationship between the saquinavir (SQV) inhibitory quotient (IQ) (virtual and genotypic) and virological response. METHODS:Eligible patients were on a PI-containing highly active antiretroviral therapy (HAART) regimen excluding SQV and had a viral load >5000 HIV-1 RNA copies/mL. The PI was switched to SQV/ritonavir (RTV) 1000/100 mg twice a day (bid) and the same two backbone nucleoside reverse transcriptase inhibitors (NRTIs) were maintained at least until week 4, when the resistance test results became available. Genotype and virtual phenotype were determined at baseline, while the SQV trough plasma concentration was determined at week 4. RESULTS:Fifty-three patients were included in the study. Mean baseline viral load and CD4 count were 137,693 copies/mL and 263 cells/microL, respectively, the mean number of previous PIs was 2.3 and the mean number of protease gene mutations (PGMs) was 4.1. Using an on-treatment analysis, at week 16 the mean increase in CD4 count was 70.9 cells/microL, viral load was <200 copies/mL in 17 out of 37 patients (45.9%), and 30 out of 45 patients (66.7%) were considered virological responders (VRs) (viral load <200 copies/mL or viral load declined > or =1 log(10) at week 16). Median virtual phenotype was 1.3 (0.6-6.9). Baseline differences were detected between VR and non-VR populations: the mean numbers of PGMs were 3.2 and 5.8 (P<0.05), the mean numbers of SQV-associated mutations were 2 and 3.8 (P<0.05), and the mean CD4 counts were 365.9 and 184.3 cells/microL (P<0.05), respectively. Mean SQV trough concentrations at week 4 were 1.1 and 1.0 microg/mL (not significant), and mean virtual IQs were 0.7 and 0.1 (P<0.01), respectively. Multivariate analysis showed that baseline PGMs >5 or SQV-associated mutations>5, virtual phenotype, baseline viral load >50,000 copies/mL, and virtual IQ <0.5, but not genotypic IQ, were the variables independently associated with non-VR. CONCLUSION:In heavily pretreated patients, the use of SQV virtual IQ or alternatively virtual phenotype, as well as PGMs, is a useful tool for the prediction of virological response.

journal_name

HIV Med

journal_title

HIV medicine

authors

Mallolas J,Blanco J,Labarga P,Vergara A,Ocampo A,Sarasa M,Arnedo M,López-Púa Y,García J,Juega J,Guelar A,Terrón A,Dalmau D,García I,Zárraga M,Martínez E,Carné X,Pumarola T,Escayola R,Gatell J

doi

10.1111/j.1468-1293.2007.00464.x

subject

Has Abstract

pub_date

2007-05-01 00:00:00

pages

226-33

issue

4

eissn

1464-2662

issn

1468-1293

pii

HIV464

journal_volume

8

pub_type

临床试验,杂志文章,多中心研究
  • Cushing's syndrome secondary to inhaled corticosteroids mimicking HIV-associated lipodystrophy.

    abstract::We report the case of an asthmatic man with HIV infection who was initially diagnosed with HIV treatment-associated lipodystrophy. Further investigations showed he had Cushing's syndrome secondary to 1600 microg of budesonide dry powder inhaler. Cushing's syndrome has not been reported previously on this normal dose o...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1468-1293.2001.00058.x

    authors: le Roux CW,Beckles MA,Besser GM,Pinching AJ,Davison AG

    更新日期:2001-04-01 00:00:00

  • The role of tenofovir alafenamide in future HIV management.

    abstract::HIV infection has become a chronic condition rather than an acute life-threatening disease in developed countries, thanks to consistent innovation and evolution of effective interventions. This has altered HIV management and created new challenges. People living with HIV (PLWHIV) are living longer and so encounter com...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1111/hiv.12401

    authors: Antela A,Aguiar C,Compston J,Hendry BM,Boffito M,Mallon P,Pourcher-Martinez V,Di Perri G

    更新日期:2016-05-01 00:00:00

  • HIV testing in community settings in resource-rich countries: a systematic review of the evidence.

    abstract:OBJECTIVES:Community HIV testing represents an opportunity for diagnosing HIV infection among individuals who may not have contact with health services, especially in hard-to-reach groups. The aim of this review was to assess the evidence for feasibility, acceptability and effectiveness of HIV testing strategies in com...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1111/j.1468-1293.2012.00992.x

    authors: Thornton AC,Delpech V,Kall MM,Nardone A

    更新日期:2012-08-01 00:00:00

  • National review of maternity care for women with HIV infection.

    abstract:OBJECTIVE:To assess adherence to the British HIV Association (BHIVA) 2001 guidelines for the management of HIV-infected pregnant women. METHODS:A survey and a case note review were carried out using structured questionnaires sent to providers of adult HIV care in the UK and Ireland. Participants were women with HIV in...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2006.00385.x

    authors: McDonald C,Curtis H,de Ruiter A,Johnson MA,Welch J,British HIV Association (BHIVA) and the BHIVA audit subcommittee.

    更新日期:2006-07-01 00:00:00

  • Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE s

    abstract:OBJECTIVES:We assessed whether changes at week 12 in markers of bone turnover, inflammation, and immune activation were associated with clinically important (≥ 5%) bone mineral density (BMD) loss from baseline to week 48 at the proximal femur (hip) and lumbar spine in the SECOND-LINE study. METHODS:We measured concent...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12882

    authors: Mwasakifwa GE,Amin J,White CP,Center JR,Kelleher A,Boyd MA

    更新日期:2020-09-01 00:00:00

  • The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.

    abstract:OBJECTIVE:This study was designed to evaluate the effects of the HIV protease inhibitor lopinavir/ritonavir on gingival epithelium growth, integrity and differentiation. METHODS:Organotypic (raft) cultures of gingival keratinocytes were established and treated with a range of lopinavir/ritonavir concentrations. To exa...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2010.00863.x

    authors: Israr M,Mitchell D,Alam S,Dinello D,Kishel JJ,Meyers C

    更新日期:2011-03-01 00:00:00

  • Euthanasia: from the perspective of HIV infected persons in Europe.

    abstract:BACKGROUND:In the debate about legalization of euthanasia very little attention has so far been given to the opinion of the patient. OBJECTIVE:To assess the opinion of persons with HIV infection in Europe. METHODS:A cross-sectional survey of persons with HIV infection attending HIV/AIDS treatment centres or HIV suppo...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1468-1293.2001.00053.x

    authors: Andraghetti R,Foran S,Colebunders R,Tomlinson D,Vyras P,Borleffs CJ,Fleerackers Y,Schrooten W,Borchert M

    更新日期:2001-01-01 00:00:00

  • Treatment initiation factors and cognitive outcome in youth with perinatally acquired HIV infection.

    abstract:OBJECTIVES:Although cognitive outcomes among perinatally infected youth have improved with highly active antiretroviral therapy (HAART), the impact of the age of initiation of treatment and the central nervous system (CNS) penetration effectiveness (CPE) of the regimen on cognitive outcomes is unknown. We aimed to desc...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12220

    authors: Lazarus JR,Rutstein RM,Lowenthal ED

    更新日期:2015-07-01 00:00:00

  • Proviral HIV-1 dynamics and evolution in patients receiving efficient long-term antiretroviral combination therapy.

    abstract:OBJECTIVES:Different experimental approaches have shown that, despite plasma viral loads under the threshold of detection, HIV-1 frequently continues to replicate in patients receiving potent antiretroviral therapy. However, whether this low-grade viral replication is sufficient for the generation of new major quasispe...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1468-1293.2000.00030.x

    authors: Birk M,Aleman S,Visco-Comandini U,Sönnerborg A

    更新日期:2000-10-01 00:00:00

  • Mitochondrial DNA assessment in adipocytes and peripheral blood mononuclear cells of HIV-infected patients with lipodystrophy according to a validated case definition.

    abstract:BACKGROUND:Several studies have compared mitochondrial DNA (mtDNA) content in tissue from HIV-1-infected patients on highly active antiretroviral therapy with and without evidence of lipodystrophy, the diagnosis of which was based on subjective clinical assessment. OBJECTIVES:The aim of this study was to assess the ut...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2007.00428.x

    authors: Casula M,van der Valk M,Wit FW,Nievaard MA,Reiss P

    更新日期:2007-01-01 00:00:00

  • Kaposi's sarcoma in HIV-infected patients: treatment options.

    abstract::Kaposi's sarcoma (KS) is the most prevalent AIDS-associated tumour, occurring in 20-30% of HIV-1-infected individuals in the early 1980s. The introduction of highly active antiretroviral therapy (HAART) has dramatically reduced the incidence of the disease and might therefore support the concept of 'opportunistic mali...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1046/j.1468-1293.2000.00027.x

    authors: Hermans P

    更新日期:2000-07-01 00:00:00

  • HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.

    abstract::The advent of potent highly active antiretroviral therapy (HAART) for persons infected with HIV-1 has led to a "new" chronic disease with complications including cardiovascular disease (CVD). CVD is a significant cause of morbidity and mortality in persons with HIV infection. In addition to traditional risk factors su...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1111/hiv.12346

    authors: Lambert CT,Sandesara PB,Hirsh B,Shaw LJ,Lewis W,Quyyumi AA,Schinazi RF,Post WS,Sperling L

    更新日期:2016-06-01 00:00:00

  • Effect of testing experience and profession on provider acceptability of rapid HIV testing after implementation in public sexual health clinics in Sydney.

    abstract:OBJECTIVES:Rapid HIV testing (RHT) is well established in many countries, but it is new in Australia since a policy change in 2011. We assessed service provider acceptability of RHT before and after its implementation in four Sydney public sexual health clinics. METHODS:Service providers were surveyed immediately afte...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12209

    authors: Conway DP,Guy R,McNulty A,Couldwell DL,Davies SC,Smith DE,Keen P,Cunningham P,Holt M,Sydney Rapid HIV Test Study.

    更新日期:2015-05-01 00:00:00

  • Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.

    abstract:OBJECTIVES:Conflicting results have been reported regarding the ability of valproic acid (VPA) to reduce the size of HIV reservoirs in patients receiving suppressive highly active antiretroviral therapy (HAART). In a randomized multicentre, cross-over study, we assessed whether adding VPA to stable HAART could potentia...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2011.00975.x

    authors: Routy JP,Tremblay CL,Angel JB,Trottier B,Rouleau D,Baril JG,Harris M,Trottier S,Singer J,Chomont N,Sékaly RP,Boulassel MR

    更新日期:2012-05-01 00:00:00

  • The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.

    abstract:BACKGROUND:Virological failure of first-generation nonnucleoside reverse transcriptase inhibitors (NNRTIs) can compromise the efficacy of etravirine as a result of the accumulation of NNRTI resistance mutations. How quickly NNRTI resistance accumulates in patients with a delayed switch from nevirapine or efavirenz desp...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2011.00943.x

    authors: Cozzi-Lepri A,Paredes,Phillips AN,Clotet B,Kjaer J,Von Wyl V,Kronborg G,Castagna A,Bogner JR,Lundgren JD,EuroSIDA in EuroCoord.

    更新日期:2012-01-01 00:00:00

  • How reliable is an undetectable viral load?

    abstract:OBJECTIVES:An article by the Swiss AIDS Commission states that patients with stably suppressed viraemia [i.e. several successive HIV-1 RNA plasma concentrations (viral loads, VL) below the limits of detection during 6 months or more of highly active antiretroviral therapy (HAART)] are unlikely to be infectious. Questio...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2009.00714.x

    authors: Combescure C,Vallier N,Ledergerber B,Cavassini M,Furrer H,Rauch A,Battegay M,Bernasconi E,Vernazza P,Hirschel B,Swiss HIV Cohort Study.

    更新日期:2009-09-01 00:00:00

  • An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.

    abstract:OBJECTIVES:Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, is a drug that is frequently included in highly active antiretroviral therapy for treatment of HIV infection. Decreased bioavailability and increased toxicity limit its use. We report a formulation of efavirenz-loaded lactoferrin nanoparticle...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12475

    authors: Kumar P,Lakshmi YS,Kondapi AK

    更新日期:2017-08-01 00:00:00

  • HIV testing strategies outside of health care settings in the European Union (EU)/European Economic Area (EEA): a systematic review to inform European Centre for Disease Prevention and Control guidance.

    abstract:OBJECTIVES:In recent years, new technologies and new approaches to scale up HIV testing have emerged. The objective of this paper was to synthesize the body of recent evidence on strategies aimed at increasing the uptake and coverage of HIV testing outside of health care settings in the European Union (EU)/European Eco...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12807

    authors: Croxford S,Tavoschi L,Sullivan AK,Combs L,Raben D,Delpech V,Jakobsen SF,Amato-Gauci AJ,Desai S

    更新日期:2020-03-01 00:00:00

  • Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific.

    abstract:OBJECTIVES:To assess second-line antiretroviral therapy (ART) virological failure and HIV drug resistance-associated mutations (RAMs), in support of third-line regimen planning in Asia. METHODS:Adults > 18 years of age on second-line ART for ≥ 6 months were eligible. Cross-sectional data on HIV viral load (VL) and gen...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.13006

    authors: Ross J,Jiamsakul A,Kumarasamy N,Azwa I,Merati TP,Do CD,Lee MP,Ly PS,Yunihastuti E,Nguyen KV,Ditangco R,Ng OT,Choi JY,Oka S,Sohn AH,Law M

    更新日期:2020-11-05 00:00:00

  • Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

    abstract:BACKGROUND:The toxicities, cost and complexity of triple combinations warrant the search for other treatment options, such as boosted protease inhibitor (PI) monotherapy. MONotherapy AntiRetroviral Kaletra (MONARK) is the first randomized trial comparing lopinavir/ritonavir monotherapy to triple combination therapy wit...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2009.00752.x

    authors: Ghosn J,Flandre P,Cohen-Codar I,Girard PM,Chaix ML,Raffi F,Dellamonica P,Ngovan P,Norton M,Delfraissy JF,MONARK Study Group.

    更新日期:2010-02-01 00:00:00

  • Sexualized drug use ('chemsex') and high-risk sexual behaviours in HIV-positive men who have sex with men.

    abstract:OBJECTIVES:The incidence of sexually transmitted infections (STIs) and HIV infection remains high in gay, bisexual, and other men who have sex with men (MSM) in the UK, and sexualized drug use ("chemsex") and injecting drug use ("slamsex") may play a part in this. We aimed to characterize HIV-positive MSM engaging in c...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12574

    authors: Pufall EL,Kall M,Shahmanesh M,Nardone A,Gilson R,Delpech V,Ward H,Positive Voices study group.

    更新日期:2018-04-01 00:00:00

  • Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.

    abstract:OBJECTIVES:Three-drug nonoccupational post-exposure prophylaxis (NPEP) typically includes co-formulated emtricitabine-tenofovir (FTC-TDF) and a protease inhibitor. However, protease inhibitors can cause significant toxicities, can interact with prescribed and illicit drugs, and work late in the viral cycle. Agents that...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/hiv.12075

    authors: McAllister J,Read P,McNulty A,Tong WW,Ingersoll A,Carr A

    更新日期:2014-01-01 00:00:00

  • Early glial activation precedes neurodegeneration in the cerebral cortex after SIV infection: a 3D, multivoxel proton magnetic resonance spectroscopy study.

    abstract:OBJECTIVES:As ∼40% of HIV-infected individuals experience neurocognitive decline, we investigated whether proton magnetic resonance spectroscopic imaging ((1) H-MRSI) detects early metabolic abnormalities in the cerebral cortex of a simian immunodeficiency virus (SIV)-infected rhesus monkey model of neuroAIDS. METHODS...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12222

    authors: Wu WE,Babb JS,Tal A,Kirov II,George AE,Ratai EM,Gonzalez RG,Gonen O

    更新日期:2015-07-01 00:00:00

  • The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy.

    abstract:OBJECTIVE:The aim of the study was to compare the metabolic and morphological effects of enfuvirtide plus an optimized background (OB) regimen vs. OB alone (control group) in treatment-experienced patients in the T-20 vs. Optimized Regimen Only (TORO) studies. METHODS:Body composition and metabolic changes were invest...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2010.00845.x

    authors: Cooper DA,Cordery DV,Reiss P,Henry K,Nelson M,O'Hearn M,Reynes J,Arastéh K,Chung J,Rowell L,Guimaraes D,Bertasso A,TORO 1 and TORO 2 Study Groups.

    更新日期:2011-01-01 00:00:00

  • Pitfalls in measuring high-density lipoprotein cholesterol concentrations in HIV-infected patients.

    abstract:OBJECTIVES:HIV infection and its treatment are associated with dyslipidaemia and increased risk of cardiovascular disease. Accurate high-density lipoprotein (HDL) cholesterol values are necessary for the management of these abnormalities, but current methods have not been properly assessed in these patients. The aim of...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2009.00772.x

    authors: Aragonès G,Beltrán R,Rull A,Marsillach J,Rodríguez F,Alí SB,Fernández-Sender L,Camps J,Joven J,Alonso-Villaverde C

    更新日期:2010-04-01 00:00:00

  • Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.

    abstract:OBJECTIVES:Apricitabine (ATC) is a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor (NRTI) with significant antiviral activity in vitro, including activity against HIV-1 with reverse transcriptase mutations that confer resistance to other NRTIs. ATC has shown promising antiviral activity and good...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1468-1293.2010.00887.x

    authors: Cahn P,Altclas J,Martins M,Losso M,Cassetti I,Cooper DA,Cox S

    更新日期:2011-07-01 00:00:00

  • Knowledge of their children's HIV status in HIV-positive mothers attending a genitourinary medicine clinic in the UK.

    abstract:OBJECTIVES:To determine whether HIV-infected mothers knew the HIV status of their children, enabling the offer of targeted testing of children at risk. METHODS:All HIV-positive women attending the genitourinary medicine clinic at a district general hospital in the United Kingdom were asked whether they had children an...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2008.00556.x

    authors: Eisenhut M,Sharma V,Kawsar M,Balachandran T

    更新日期:2008-04-01 00:00:00

  • Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.

    abstract:OBJECTIVES:Pregnant women experience physiological changes during pregnancy that can have a significant impact on antiretroviral pharmacokinetics. Ensuring optimal plasma concentrations of antiretrovirals is essential for maternal health and to minimize the risk of vertical transmission. Here we describe atazanavir/rit...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12164

    authors: Else LJ,Jackson V,Brennan M,Back DJ,Khoo SH,Coulter-Smith S,Lambert JS

    更新日期:2014-11-01 00:00:00

  • Virological and immunological profiles among patients with undetectable viral load followed prospectively for 24 months.

    abstract:OBJECTIVE:To quantify HIV-RNA in plasma, in lymphoid tissue and proviral DNA in peripheral blood mononuclear cells and to relate these to immunological markers among patients with plasma viral load counts of

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1468-1293.2003.00119.x

    authors: Katzenstein TL,Ullum H,Røge BT,Wandall J,Dickmeiss E,Barrington T,Skinhøj P,Gerstoft J

    更新日期:2003-01-01 00:00:00

  • Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010.

    abstract:OBJECTIVES:Adipose tissue affects several aspects of the cellular immune system, but prior epidemiological studies have differed on whether a higher body mass index (BMI) promotes CD4 T-cell recovery on antiretroviral therapy (ART). The objective of this analysis was to assess the relationship between BMI at ART initia...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12259

    authors: Koethe JR,Jenkins CA,Lau B,Shepherd BE,Silverberg MJ,Brown TT,Blashill AJ,Anema A,Willig A,Stinnette S,Napravnik S,Gill J,Crane HM,Sterling TR,North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

    更新日期:2015-10-01 00:00:00